Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on June 6, 2025
Renault Group finalises a strategic partnership with Wandercraft, a leader in next generation robotics
GlobeNewswire
·
June 6, 2025
Renault Group announces the closing of the acquisition of a minority investment in Wandercraft, a French company with an undisputed leadership in AI-enabled robotic exoskeletons for people with reduced mobility, currently deploying its technology towards …
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
GlobeNewswire
·
June 6, 2025
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform …
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
GlobeNewswire
·
June 6, 2025
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said …
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
GlobeNewswire
·
June 6, 2025
New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with ZORYVE cream 0.15% or ZORYVE cream 0. …
PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing
GlobeNewswire
·
June 6, 2025
Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership …
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June …
Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million
GlobeNewswire
·
June 6, 2025
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG …
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
GlobeNewswire
·
June 6, 2025
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 …
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
GlobeNewswire
·
June 6, 2025
RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the …
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
GlobeNewswire
·
June 6, 2025
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to …
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
GlobeNewswire
·
June 6, 2025
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment-resistant depression (TRD) - SAN …
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
GlobeNewswire
·
June 6, 2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
GlobeNewswire
·
June 6, 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 …
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
GlobeNewswire
·
June 6, 2025
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. …
浩鼎自创ADC平台GlycOBI® 首宗技术合作案 携手美国TegMine开发ADC
GlobeNewswire
·
June 6, 2025
台湾, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技（以下简称「浩鼎」）（4174.TWO）今（06/06）宣布，与美国TegMine Therapeutics, Inc.（以下简称「TegMine」）签署ADC研发服务合约（Master Services Agreement, MSA）；TegMine 是一家总部位于美国旧金山的生物制药公司，专注于开发针对癌症相关糖蛋白的创新抗体疗法。浩鼎则致力于开发抗癌新药及聚焦研发次世代抗体药物复合体（ADCs）。 根据合约，浩鼎将与 …
浩鼎自創ADC平台GlycOBI® 首宗技術合作案 攜手美國TegMine開發ADC
GlobeNewswire
·
June 6, 2025
台灣, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技（以下簡稱「浩鼎」）（4174.TWO）今（06/06）宣布，與美國TegMine Therapeutics, Inc.（以下簡稱「TegMine」）簽署ADC研發服務合約（Master Services Agreement, MSA）；TegMine 是一家總部位於美國舊金山的生物製藥公司，專注於開發針對癌症相關醣蛋白的創新抗體療法。浩鼎則致力於開發抗癌新藥及聚焦研發次世代抗體藥物複合體（ADCs）。 根據合約，浩鼎將與 …